JP7133808B2 - Radiopharmaceutical administration device - Google Patents

Description

TECHNICAL FIELD The present invention relates to a radiopharmaceutical administration device for administering a radiopharmaceutical to a living body.

It is known that radiopharmaceuticals contain radionuclides that decay over time according to their own half-lives and emit radiation at that time. For this reason, it is known that an automatic administration device is used to prevent workers from being exposed to radiation when working with radioactive drugs. Such a radiopharmaceutical administration device is described, for example, in US Pat. The radiopharmaceutical administration device described in Patent Document 1 includes a container placement portion in which a shielded container containing a radiopharmaceutical stored in a vial bottle is arranged, an infusion tube that forms a flow path for the radiopharmaceutical, and a flow path provided on the flow path. A syringe or the like is provided for withdrawing the radiopharmaceutical from the channel switching member and the shielding container and administering it to the living body. These structures are covered with radiation shielding members.

Japanese Patent Application Laid-Open No. 2006-15055

However, the radiation shielding member of the radiopharmaceutical administration apparatus described in Patent Document 1 has a substantially rectangular parallelepiped external appearance, and the shielding space formed therein also has a substantially rectangular parallelepiped shape. Such a radiation shielding member is designed according to the flow path switching member, syringe, etc., which are arranged inside and which require a large space for installation. Therefore, in the shielded space, there may be a space (surplus space) that is not used for installing the member around the member having a relatively small installation space. In this way, the radiopharmaceutical administration device described in Patent Document 1, in which a surplus space is generated in the device, is disadvantageous in miniaturizing the device, and there is room for further reducing the installation space.
The present invention has been made in view of these points, and relates to a radiopharmaceutical administration apparatus that is advantageous in miniaturizing the external dimensions and saving the space required for installation.

A radiopharmaceutical administration device of the present invention is a radiopharmaceutical administration device for administering a radiopharmaceutical to a living body, comprising: a container holding portion for holding a shielded container in which a drug container of the radiopharmaceutical is accommodated; a configuration mounting portion to which a plurality of flow path constituting members constituting part of a flow path connected to the drug container housed in the container are attached; A shielding member that shields radiation emitted from the radiopharmaceutical, and a device housing that covers at least a portion of the shielding member, and the shielding member has a portion of the upper surface in the installation direction that is the other portion of the upper surface. and has a loose insertion space in which the flow path drawn out from the shielding member is loosely inserted above the low surface outside the shielding area covered by the shielding member.

TECHNICAL FIELD The present invention relates to a radiopharmaceutical administration apparatus that is advantageous in miniaturizing the outer dimensions and saving the space required for installation.

BRIEF DESCRIPTION OF THE DRAWINGS It is a figure for demonstrating the outline|summary of embodiment of this invention. BRIEF DESCRIPTION OF THE DRAWINGS It is a perspective view which shows the external appearance of the radiopharmaceutical administration apparatus of 1st embodiment. FIG. 3 is a front view of a partial cross-section of a part of the radiopharmaceutical administration device shown in FIG. 2 taken along the xz plane. FIG. 3 is a left side view of a partial cross-section of a part of the radiopharmaceutical administration device shown in FIG. 2 taken along the yz plane. FIG. 2 is a right side view of a partial cross-section of a part of the radiopharmaceutical administration device shown in FIG. 1 cut along the yz plane. Fig. 2 is a front view of a detachable cassette attached to the radiopharmaceutical administration device; FIG. 7 is a rear view of the detachable cassette shown in FIG. 6; FIG. 7 is a top view of the removable cassette shown in FIG. 6; It is a figure which shows the modification of the container holder of 1st embodiment. It is a bottom view of the removable cassette of the second embodiment. It is a front view of the detachable cassette of the second embodiment. It is a rear view of the detachable cassette of 2nd embodiment. (a) and (b) are diagrams for explaining a needle unit according to a second embodiment.

[Overview]
First, the outline of the present invention will be described prior to concrete description of the first embodiment and the second embodiment of the present invention. In this specification, the first embodiment and the second embodiment are also collectively referred to as the present embodiment. In the description of the outline and the drawings shown in this embodiment, the same constituent elements are denoted by the same reference numerals, and the description thereof will be omitted as appropriate. Moreover, the drawings of the present embodiment are examples of the constituent members of the radiopharmaceutical administration apparatus of the present invention, and the arrangement, function, and positional relationship of each constituent member, and do not limit the specific configuration.

FIG. 1 is a diagram for explaining an outline of an embodiment of the present invention. A radiopharmaceutical administration device 1 of this embodiment is a radiopharmaceutical administration device for administering a radiopharmaceutical to a living body. The radiopharmaceutical administration apparatus 1 includes a container holding portion (corresponding to the container placement portion 12 in FIGS. 3 and 5) that holds a shielding container containing a drug container of a radioactive drug, and a radiopharmaceutical contained in the container holding portion. and a plurality of structural attachment portions (corresponding to the flow channel forming member arrangement portion 14 in FIGS. 3 and 4) that constitute part of the flow channel connected to the container. The radiopharmaceutical administration device 1 includes a shielding member 21 that covers at least a portion of the container holding portion or the component mounting portion, and a device housing 20 that covers at least a portion of the shielding member 21 . The shielding member 21 has a lower surface portion 211b in which a part of the upper surface 211 in the installation direction is lower than the other portion (higher surface portion 211a) of the upper surface 211, and a radioactive material drawn out from the shielding member 21 above the lower surface portion 211b. It has a loose insertion space 50 into which the flow path 31b is loosely inserted.

Among the above, the radiopharmaceutical administration device may have a function of administering a radiopharmaceutical, and may also have other functions such as dispensing and synthesis. Here, regarding the installation direction, the z direction of the x, y, z coordinates shown in FIG. 1 is defined as "up" and the -z direction is defined as "down" according to the direction of gravity. In the example shown in FIG. 1, the side of the radiopharmaceutical administration device 1 viewed in the y direction is the "front" or "front" of the radiopharmaceutical administration device 1, and the side of the radiopharmaceutical administration device 1 viewed in the -y direction is the ""rear" or "rear".
Since the upper surface 211 has a high surface portion 211a and a low surface portion 211b, the shielding member 21 of the radiopharmaceutical administration apparatus 1 has steps. A virtual rectangular parallelepiped having the maximum vertical, horizontal, and depth lengths of the shielding member 21 is overlapped with the actual shielding member 21, and the missing portion of the shielding member 21 with respect to the virtual rectangular parallelepiped is subsequently cut out. Also referred to as region 210 . In the radiopharmaceutical administration device 1 , the notch region 210 is used as the loose insertion space 50 .

The radioactive channel 31 b loosely inserted into the insertion space 50 is a channel through which a liquid containing a radioactive drug flows, and is housed in the device housing 20 , preferably in the shielding member 21 . The radiopharmaceutical administration device 1 includes a channel guide portion 16 that guides the radioactive channel 31b from the opening 211c formed in the lower surface portion 211b to the opening 211d of the device housing 20. As shown in FIG. The flow path guiding portion 16 is accommodated in the device housing 20 and can be pulled out in the direction of the arrow A from the device housing 20 as needed. In addition to the length from the opening 211c to the opening 211d, the radioactive flow path 31b of such a radiopharmaceutical administration device 1 requires a length to be pulled out together with the flow path guiding portion 16. FIG. In order to secure such a length allowance, the radioactive channel 31b is loosely inserted into the loose insertion space 50 in this embodiment.

Also, in this embodiment, it is not necessary to route the radioactive channel 31b above the shielding member 21 and route the radioactive channel 31b to other locations (for example, the back of the radiopharmaceutical administration device). Therefore, when compared with a known radiopharmaceutical administration device in which the radioactive flow path 31b is routed from the back surface of the radiopharmaceutical administration device 1, in the radiopharmaceutical administration device 1 of the present embodiment, the flow path is routed. It becomes possible to arrange relatively large components such as a power supply and a control unit in the space. Such a point is more effective for miniaturization of the radiopharmaceutical administration device 1 .
Furthermore, the configuration in which the radioactive channel 31b is routed above the shielding member 21 allows the operator to operate the radioactive channel 31b while standing in front of the radiopharmaceutical administration device 1 . Therefore, the work space around the radioactive drug administration device 1 can be reduced, and the installation area of the radiopharmaceutical administration device 1 can be reduced.

[First embodiment]
(overall structure)
Next, the overall configuration of the radiopharmaceutical administration device 1 of the first embodiment will be described. Each of FIGS. 2 to 5 is a diagram showing the radiopharmaceutical administration device 1. FIG. 2 is a perspective view showing the appearance of the radiopharmaceutical administration device 1, and FIGS. 3 to 5 are partial cross-sectional views of the radiopharmaceutical administration device 1 viewed from the front, left side, and right side, respectively. These partial cross-sectional views show cross-sections of the shielding region and its peripheral structure, and show the appearance of other configurations. FIG. 3 is a partial sectional view taken along the xz plane of a part of the radiopharmaceutical administration device 1 in which the shielding door 10 is not attached to the device housing 20. FIG. 4 and 5 are partial cross-sectional views of the shielded region of the radiopharmaceutical administration device 1 taken along the yz plane. As shown in FIGS. 2 to 5 , in the radiopharmaceutical administration device 1 , the vial bottle 7 containing the radiopharmaceutical 27 is placed inside together with the shielding container 5 . The radiopharmaceutical administration device 1 extracts a radiopharmaceutical 27 and administers it to the living body.

The radiopharmaceutical 27 is liquid, and its type is not particularly limited. Examples of such a radiopharmaceutical 27 include, for example, a radiopharmaceutical containing positron-emitting nuclides (fluorine-18, nitrogen-13, carbon-11, copper-64, etc.) for PET (Positron Emission Tomography) examination, For example, [ ¹⁸ F]-2-deoxy-2-fluoro-D-glucose), [ ¹⁸ F] flutemetamol, [ ¹⁸ F] florbetapyr, [ ¹⁸ F] florbetaben, [ ¹⁸ F] fluciclovin, [ ¹⁸ F] fluoroethyl Tyrosine, [ ¹⁸ F]fluoromisonidazole, [ ¹⁸ F]dopamine, [ ¹⁸ F]sodium fluoride, [ ¹¹ C]methionine, [ ¹¹ C]choline derivatives, [ ¹¹ C]acetic acid, [ ⁶⁴ Cu]dithiosemi Examples include carbazone derivatives, and radionuclides for SPECT (Single Photon Emission Computed Tomography) examination (technetium-99m, thallium-201, gallium-68, chromium-51, iodine-123 , iodine-125, etc.), or a radiopharmaceutical containing a radionuclide for internal radiotherapy (iodine-131, etc.).

The radiopharmaceutical administration device 1 has a configuration for extracting and administering the radiopharmaceutical 27 and a configuration for reducing leakage of radiation to the outside. The shielding member 21 and the device housing 20 are configured to reduce the leakage of radiation to the outside, and among these, the shielding member 21 mainly has a large radiation shielding function. The shielding member 21 only needs to individually cover at least a part of the container placement portion 12 (container holding portion) or the flow path component placement portion 14 (configuration attachment portion), and at least one of the container holding portion and the configuration attachment portion. Although the parts may be covered as a unit, it is preferred that there are a plurality of shielding areas that individually shield at least a portion of the container holding part or the component mounting part. In this embodiment, the case where the shielding member 21 is provided with two areas (S1, S2) for individually shielding at least part of the container holding portion and the component mounting portion will be described.

The shielding member 21 has a plurality of shielding walls 21d to 21j that constitute the flow path component placement portion 14, and a shield door 10a (FIG. 2) that opens or closes the flow path configuration member placement portion 14, thereby forming a shielding area inside. Form S2. As shown in FIG. 4, the shielding door 10a comprises an outer door 100 having an outer surface exposed to the outside of the radiopharmaceutical administration apparatus 1, and an inner door 110 facing the inner surface, which is the rear surface of the outer surface of the outer door 100. contains. Here, facing means simply facing each other, and the distance between the two is irrelevant. In the example shown in FIG. 4, the rear surface of the outer door 100 and the inner door 110 are in contact with each other.
In addition, the shielding member 21 includes a plurality of shielding walls 21a constituting the container arrangement portion 12, a shielding wall 21d shared with the flow channel component arrangement portion 14, and a shield door 10a for opening or closing the flow channel component arrangement portion 14. (FIG. 2) forms a shielding region S1 inside. Further, the shielding door 10b has a grip portion 11 (FIG. 2), and an operator can grip the gripping portion 11 to open or close the shielding door 10b.

The outer door 100 is formed of an A layer 100a having a high radiation stopping power and a B layer 100b having a lower radiation stopping power than the A layer. Here, the stopping power of radiation refers to the percentage of radiation energy lost per unit length along the path that a charged particle travels through a material.

As shown in FIGS. 4 and 5, a waste liquid bottle placement section 18 for storing a waste liquid bottle 180 in which the waste liquid of the radioactive drug 27 is discarded can be opened and closed behind the flow path component placement section 14 of the apparatus housing 20. A covering waste liquid bottle storage door 10c is provided. The waste liquid bottle arrangement portion 18 is a shielded space surrounded by shielding walls 21n, 21o, 21p and a shielding wall 21q. The device housing 20 is a metal housing that covers the container arrangement portion 12 , the flow path component arrangement portion 14 and the waste liquid bottle arrangement portion 18 . However, in the first embodiment, one surface of the flow path component arrangement portion 14 and the container arrangement portion 12 is covered with the shielding doors 10a and 10b, which are shielding members. partially covered.
A channel housing door 10 d that covers the channel guiding portion 16 is provided on the left side surface of the device housing 20 . Since the grip portion 10cc and the grip portion 10dd are provided on the waste liquid bottle storage door 10c and the channel storage door 10d, respectively, the operator can grip the grip portion 10cc and the grip portion 10dd to open the waste liquid bottle storage door 10c and the flow channel storage door 10c. The accommodation door 10d can be opened and closed. In the first embodiment, the channel housing door 10d is pulled out movably in the width direction and in the direction away from the housing body.

In addition, as shown in FIG. 2, a power switch 64 for switching power on/off and an external communication connector 63 for the radiopharmaceutical administration device 1 to communicate with the outside are provided on the front of the device housing 20 . An operation unit 6 is provided in front of the top surface of the housing for an operator to instruct automatic administration to the radiopharmaceutical 27. Displays the information of the living body, etc. Further, the radiopharmaceutical administration device 1 has a display 65 such as a touch panel on the upper surface for receiving input by the operator. An emergency stop switch 62 for stopping the operation of the radiopharmaceutical administration device 1 in an emergency is provided behind the upper surface of the device housing 20, and a radioactive drug 27 is located in front of the emergency stop switch 62 on the upper surface. A suspension stand 35 is provided on which the physiological saline bag 3 containing physiological saline for pushing out or cleaning the flow path can be suspended.

Next, the internal structure of the radiopharmaceutical administration device 1 will be described. The radiopharmaceutical administration device 1 of the first embodiment includes a container holder 122 in a container placement section 12 that is a container holding section that holds the shielded container 5 containing the vial bottle 7 of the radiopharmaceutical 27 . In addition, the radiopharmaceutical administration apparatus 1 constitutes a part of the flow path connected to the vial bottle 7 housed in the container holder 122, and at least a part thereof has a size different from that of the other part. A configuration mounting portion to which the flow path forming member is mounted is provided. The structural attachment portion of the first embodiment is the flow path forming member placement portion 14, and the flow path forming member placement portion 14 includes the saline solution flow path 31a, the radioactive flow path 31b, the first syringe 36a, the second syringe 36a, and the second A syringe 36b and three channel switching members 33a, 33b, 33c are attached, and an air vented filter 32 is attached on the radioactive channel 31b.

Moreover, the radiopharmaceutical administration device 1 includes a shielding member 21 as a configuration for reducing leakage of radiation to the outside. The shielding member 21 is composed of a plurality of shielding walls 21a to 21k provided to individually surround the shielding regions S1 and S2. In addition, the container arrangement portion 12 is arranged in the shielded area S1, and the flow path component arrangement portion 14 is arranged in the shielded area S2.

In addition, the radiopharmaceutical administration apparatus 1 has a guide path 160, which is a flow path guide portion 16 that holds the radioactive flow path 31b between the opening 211c formed in the shielding member 21 and the opening 211d formed in the apparatus housing 20. I have. Such a guiding path 160 can be said to statically guide the radioactive channel 31b from the opening 211c to the opening 211d. The channel guiding portion 16 has a guiding path 160 through which the radioactive channel 31b is inserted, a channel inlet 161, and a channel outlet 162. ) to pull in the radioactive channel 31b loosely inserted in the loose insertion space 50 and guide it to the outside of the device. In addition, the flow channel guiding portion 16 of the first embodiment enables the radioactive flow channel 31b to move in the width direction (-x direction) of the device housing 20. As shown in FIG. At this time, the radioactive channel 31b held by the guideway 160 moves in the -x direction together with the guideway 160 and receives tension. In the first embodiment, as described above, the radioactive channel 31b is bent and loosely inserted in the loosely inserted space 50, thereby hindering the movement of the channel guiding portion 16. , or the radioactive channel 31b can be prevented from coming off from the connector 34 or the like.

Next, the shielding member 21 will be described. As shown in FIG. 3, the radiopharmaceutical administration apparatus 1 forms a shielding area S1 with shielding walls 21a, 21b, 21c, 21d, and 21j, and includes a container placement section 12 within the shielding area S1. The shielding walls 21d, 21e, 21f, 21g, 21h, 21i, 21j, and 21k form a shielding area S2, and the passage forming member arrangement portion 14 is provided in the shielding area S2. In addition, the radiopharmaceutical administration device 1 has a shielding wall 21m that covers the upper part of the flow path guide section 16 . Furthermore, the radiation is shielded by the shielding walls 21n, 21o, 21p, and 21q inside the waste liquid bottle arrangement portion 18 that stores the waste liquid of the radioactive drug 27 as well. The shielding walls 21a to 21q of the radiopharmaceutical administration device 1 reduce the radiation exposure of the operator and protect the motors, actuators, and the like that constitute each driving mechanism of the device, which will be described later.

Further, as shown in FIGS. 4 and 5, the radiopharmaceutical administration device 1 includes an uninterruptible power supply (UPS) 70a that supplies power to the radiopharmaceutical administration device 1, and driving components for administering the radiopharmaceutical. It has electric devices such as a control unit 70b and a transformer 70c for controlling the . The control unit 70b includes a small CPU that executes arithmetic processing for determining the dose of the radioactive drug 27, a memory device, and a driver unit such as a motor and an actuator provided inside the radioactive drug administration apparatus 1. Moreover, the radiopharmaceutical administration device 1 is provided with a printer 40 , and can output administration information and the like via the printer 40 after the radiopharmaceutical 27 has been administered.

(Container placement part)
Next, the container placement section 12 will be described. In this embodiment, the container placement portion 12 corresponds to a container holding portion. As shown in FIGS. 3 and 5, the container arranging unit 12 includes a container holder 122 for holding the shielded container 5 containing the vial bottle 7 containing the radioactive drug 27 as a configuration for administering the radioactive drug 27, a radioactive A needle unit arrangement portion 124 is arranged to which a needle unit 128 for extracting the medicine 27 from the vial bottle 7 is attached. The needle unit 128 has a needle holder 127 that detachably holds a drug extraction needle 125 for extracting the radioactive drug from the vial bottle 7 and an aeration needle 126 that is punctured by the vial bottle 7 . The container placement portion 12 is surrounded by shielding walls 21a, 21b, 21c, 21d, and 21j, and the front side of the apparatus housing 20 is covered with a shielding door 10b so as to be openable and closable.
The container holder 122 of the container placement section 12 is provided inside the device housing 20 and positioned below the needle unit placement section 124 . In addition, the container holder 122 has an inclined surface 123 that holds the shielding container 5 in an inclined manner. It is possible to descend to the vicinity of the bottom of 7, and a small amount of radiopharmaceutical 27 can be extracted.

Needle unit arrangement portion 124 has a space in which needle unit 128 can be driven at a position corresponding to a needle guide portion (not shown). Needle unit 128 is mechanically connected to needle holder 127 (127a, 127b). The needle unit 128 , which is one of the flow path constituent members, has a needle drive mechanism 129 that controls the amount of drive of the needle holder 127 . Needle driving mechanism 129 is composed of a stepping motor or the like, and the driving amount of needle driving mechanism 129 is transmitted to needle holding portion 127 which is mechanically connected, and needle holding portion 127 moves up and down within needle unit placement portion 124 .

(Flow path constituent member)
Next, the flow path forming member will be described. The flow path constituting members include a first needle holding portion 127a and a second needle holding portion 127b (FIG. 5) that detachably hold the needle body to be inserted into the shielding container 5 containing the radiopharmaceutical 27, and a first needle holding portion 127b. A needle unit 128 having a portion 127a and a second needle holding portion 127b, a radioactive channel 31b forming a channel connected to the radioactive drug 27 in communication with the shielding container 5 containing the radioactive drug 27, and physiological saline saline flow channel 31a, channel switching members 33a, 33b, and 33c provided on the channel for switching the channel, a first syringe 36a mainly used for extracting the radiopharmaceutical, and mainly physiological saline It consists of a second syringe 36b used for extraction and an air-vented filter 32 for removing air on the flow path. In the present specification, the term “channel” simply refers to a portion of the entire channel through which the radioactive drug 27 or physiological saline flows in the radiopharmaceutical administration device 1 .

The above-described flow path forming member can be attached directly or indirectly to the device housing 20 . In the first embodiment, an example in which the flow path forming member is indirectly attached will be described. In this case, each channel forming member is attached to a detachable cassette 13 which is a substrate mountable to the device housing 20, and the detachable cassette 13 can be mounted to the device housing 20 together with the flow channel forming member.
6, 7 and 8 are diagrams for explaining the removable cassette 13. FIG. 6 is a front view of the removable cassette 13, FIG. 7 is a rear view of the removable cassette 13, and FIG. It is a top view. As shown in FIGS. 6 to 8, the detachable cassette 13 includes a tube holding portion 132 holding a saline solution channel 31a and a radioactive channel 31b, and switching members holding channel switching members 33a, 33b, and 33c for switching the channels. It has a main substrate 130 having a holding portion 135 , a syringe holding portion 136 holding the first syringe 36 a and the second syringe 36 b , and a filter holding portion 138 holding the air vented filter 32 . According to such a detachable cassette 13, while holding the saline solution channel 31a, the radioactive channel 31b, the channel switching members 33a, 33b, 33c, the first syringe 36a, the second syringe 36b, and the air vented filter 32, , By attaching to the device housing 20 of the radiopharmaceutical administration device 1, the saline solution channel 31a, the radioactive channel 31b, the channel switching members 33a, 33b, 33c, the first syringe 36a, the second syringe 36b and the air vented filter Disposable members such as 32 can be easily set. In addition, after administration of the radiopharmaceutical 27 , these disposable members can be easily removed from the device housing 20 together with the detachable cassette 13 .

Further, the main substrate 130 has a mounting hole 19 and a handle portion 17 for attachment to the flow path component placement portion 14 . A flow channel component holding portion 144 (for example, a convex portion) is provided at a position corresponding to the mounting hole 19 of the flow channel component placement portion 14, and the mounting hole 19 and the flow channel component holding portion 144 are engaged. , the main substrate 130 can be attached to the flow passage component placement portion 14 . However, this attachment format is only an example, and if it is possible to attach the main substrate 130 to the flow path component placement portion 14, the structure on the side of the main substrate 130 and the structure of the flow path configuration member holding portion 144 are particularly Not limited.

A plurality of tube holders 132 may be provided, and can hold the saline solution channel 31a and the radioactive channel 31b. , the number and shape of which are not particularly limited as long as the radioactive channel 31b can be routed. For example, in FIG. 6, eight tube holders 132 are provided.
In the first embodiment, the main substrate 130 has, for example, three switching member holding portions 135 arranged side by side in the width direction and below the syringe holding portions 136 . The switching member holding portion 135 is formed in a circular disk shape when viewed from the front, is provided on the main substrate 130 in a state of penetrating the main substrate 130, and is rotatable relative to the main substrate 130. It is held by the main board 130 .

The syringe holding portion 136 of the first embodiment consists of two, a first syringe holding portion 136a and a second syringe holding portion 136b, and the two syringe holding portions are arranged on the same plane and adjacent to each other on the left and right. 6, the first syringe holding portion 136a is arranged on the left side of the second syringe holding portion 136b. The filter holding portion 138 has a shape capable of holding the air vented filter 32 and is not particularly limited in shape and position as long as it is positioned so as not to interfere with other components. If so, it is preferably positioned below the cutout region 210 .

The detachable cassette 13 further includes a sub-board 131 having two needle holding portions 127, a first needle holding portion 127a and a second needle holding portion 127b, and a needle guide portion 133 in which each needle holding portion can move. , and the sub-board 131 is fixed to the main board 130 . The main board 130 and the sub-board 131 are each formed in a board shape and arranged vertically. Also, the main board 130 and the sub-board 131 are connected at right angles to each other by connecting members 139 and are provided in parallel with each other. That is, the plane on which the main board 130 is arranged and the plane on which the sub-board 131 is arranged are provided on different planes parallel to each other. According to the detachable cassette 13 having the main board 130 and the sub board 131, there is no need to directly provide the needle holding part 127 and the needle guide part 133 to the device housing 20 of the radiopharmaceutical administration device 1, and the needle, which is a disposable member, can be used. It is easy to set and remove the body.

For example, the medicine extraction needle 125 can be attached to the first needle holding portion 127a, and the ventilation needle 126 can be attached to the second needle holding portion 127b. The first needle holding portion 127 a and the second needle holding portion 127 b are movable along linear guide holes 134 a and 134 b formed in the sub-board 131 . That is, the first needle holding portion 127a is movable along the guide hole 134a, and the second needle holding portion 127b is movable along the guide hole 134b. In the first embodiment, the guide holes 134a and 134b are arranged adjacent to each other, the guide hole 134a extending vertically, and the guide hole 134b slanting downward in a direction approaching the guide hole 134a. ing.
Note that the detachable cassette 13 is not limited to such a configuration. Any substrate may be used as long as it has a Such a substrate is preferably a substrate that is detachable from the device housing 20 like the detachable cassette 13 . In addition, in the first embodiment, the detachable cassette 13 to which the channel forming member is mounted is one of the channel forming members.

(Flow path component arrangement portion)
Next, the flow path forming member placement portion 14 will be described. In the first embodiment, the flow path forming member arrangement portion 14 corresponds to the structural attachment portion. Further, in the first embodiment, an example in which the flow path forming member is attached to the flow path forming member placement portion 14 via the detachable cassette 13 described above will be described. However, the first embodiment is not limited to the configuration in which the flow path forming member is attached to the flow path forming member arrangement portion 14 via the detachable cassette 13, and the flow path forming member is directly attached to the radiopharmaceutical administration device 1. good too. In such a case, members other than the mounting hole 19 and the handle portion 17 of the main substrate 130 shown in FIG. 135, a first syringe holding portion 136a, and a second syringe holding portion 136b) are formed integrally with the flow path forming member arrangement portion 14, and this substrate functions as a structural mounting portion.

The radiopharmaceutical administration device 1 of the first embodiment extracts the radiopharmaceutical 27 from the vial bottle 7 in the shielded container 5 through the flow path 31d constituting the flow path of the radiopharmaceutical 27, and administers the extracted radiopharmaceutical 27. One or a plurality of syringe driving units 142 for driving the plunger portions 37a and 37b of the first syringe 36a and the second syringe 36b for the purpose, and the flow path constituting member holding portion fitted with the detachable cassette 13 equipped with the flow path constituting member 144, and a channel switching member holding portion 146 that is provided on the channel and holds channel switching members 33a, 33b, and 33c that switch the channels. The syringe driving portion 142 is positioned above the flow path component placement portion 14 and is provided above the flow channel switching member holding portion 146. The flow channel switching member holding portion 146 is positioned above the flow channel configuration member placement portion. 14 , and the flow path forming member holding portion 144 is positioned substantially in the center of the flow path forming member placement portion 14 . Here, the approximate center is not particularly limited as long as it is positioned lower than the syringe driving portion 142 and higher than the flow path switching member holding portion 146 in the vertical direction. Further, the flow path forming member holding portion 144 of the first embodiment has a concave shape (concave portion). However, the channel forming member holding portion 144 may be, for example, a convex portion provided with a concave portion on the side of the radiopharmaceutical administration device 1 and serving as the concave portion. Furthermore, the flow path component holding part 144 is not limited to a configuration that fits with the radiopharmaceutical administration device 1, and any configuration that engages the radiopharmaceutical administration device 1 so that the detachable cassette 13 is fixed can be used. can be anything.

The syringe drive unit 142 is provided in the device housing 20 and can move up and down using a motor 300 as a drive source, as shown in FIG. The syringe driving portion 142 is provided at a position corresponding to the plunger portion 37a of the first syringe 36a and the plunger portion 37b of the second syringe 36b, which are part of the flow path forming members, and is fitted with the respective plunger portions. 143a and 143b, and the plunger fitting portions 143a and 143b are shaped to have engagement grooves that are open to the front side of the device (-y direction in FIG. 2). Therefore, the plunger portions 37a and 37b of each syringe are held by fitting the first syringe 36a and the second syringe 36b into the plunger fitting portions 143a and 143b from the device front side.

Further, the motor 300, which is a driving source, vertically moves the respective plunger fitting portions 143a and 143b, and vertically moves the held plunger portions 37a and 37b individually. Here, the motor 300 is preferably a stepping motor or the like that is driven with high accuracy according to a control signal. Further, the line of flow of the syringe driving portion 142 is not particularly limited as long as it does not interfere with other components when the plunger fitting portions 143a and 143b move up and down. has openings 147a and 147b extending in the moving direction (vertical direction or z-direction). The openings 147a and 147b function as guide holes when the plunger fitting portions 143a and 143b move up and down. Also, in the first embodiment, the motor 300 is shown as the power source of the syringe drive unit 142, but the drive source is not particularly limited, and an actuator such as a cylinder may be used as the drive source.

The channel forming member holding portion 144 is provided in the device housing 20 and is not particularly limited as long as it can hold the channel forming member that forms the channel used for administering the radiopharmaceutical 27 . The flow path forming member holding portion 144 has a convex portion that fits into the mounting hole 19 provided in the detachable cassette 13 , and indirectly mounts and holds the flow path forming member on the device housing 20 .

The channel switching member holding portion 146 is provided in the device housing 20 and is a plurality of channel switching member holding portions that hold the channel switching members 33a, 33b, and 33c that are part of the channel constituting members. The channel switching members 33a, 33b, and 33c are typically three-way stopcocks, and the first embodiment is also a three-way stopcock. In the first embodiment, for example, three passage switching member holding portions 146 are provided corresponding to the passage switching members 33a, 33b, and 33c, one of which is attached to the plunger fitting portion 143a of the first syringe. One of them is arranged in the lower part, and the other is arranged in the lower part of the plunger fitting part 143b of the second syringe, and they are arranged in parallel in the horizontal direction. The channel switching member holding portion 146 has engaging grooves that are open to the front side (−y direction) of the apparatus, and the channel switching members 33a, 33b, and 33c are engaged with the engaging grooves from the front side. let and hold. Each channel switching member holding portion may be formed in a disk shape, for example, when viewed from the front of the device, and is provided so as to be independently rotatable with respect to the device housing 20. For example, as shown in FIG. The flow path switching members 33a, 33b, and 33c are rotated according to the rotation of the motor 310 to switch the flow path.

(flow path guiding part)
Next, the flow-path guidance part 16 is demonstrated. As shown in FIGS. 4 and 5, in the first embodiment, the flow channel guiding portion 16 is configured to guide the saline solution flow channel 31a and the radioactive flow channel 31b through the shielding wall 21g that constitutes the shielding region S2. Plays the role of guiding to the outside. The flow path guiding portion 16 is provided at a position higher than the shielding area in the vertical direction and at a position higher than the loose insertion space 50 . In addition, the flow path guiding portion 16 is positioned away from the widthwise center line L of the loose insertion space 50 in the widthwise direction of the device housing 20 and in the direction away from it.

As shown in FIG. 4, the flow path guide portion 16 has a guide path 160 that accommodates the flow path led out from the shield wall 21g. The guiding path 160 has a channel inlet 161 for introducing the channel at one end and a channel outlet 162 for leading the channel at the other end. In the first embodiment, the channel inlet 161 is provided at a position lower than the channel outlet 162, and the guide path 160 is inclined toward the front of the apparatus. Further, the channel inlet 161 is provided near the upper portion of the notch region 210, and the channel outlet 162 is provided near the center of the upper side surface of the apparatus housing 20 in the depth direction.
The saline solution channel 31a and the radioactive channel 31b led out from the shielding wall 21g are loosely inserted into the loose insertion space 50 in a bent state. The saline flow path 31a is directly led out from the side of the apparatus, and the radioactive flow path 31b is introduced into the flow path inlet 161 by the flow path guide section 16, and then continues to the flow path outlet 162 via the guide path 160. is guided to the outside of the device. It is preferable to provide a shielding wall 21m above the guideway 160 in order to reduce the radiation exposure of the worker standing in front of the apparatus when the radioactive drug 27 passes through the flow path guided by the guideway 160. be.

Further, in the first embodiment, the flow path guiding portion 16 is movable in the width direction and away from the device housing 20 (the left direction in FIG. 3 and the front direction in FIG. 4) using a rail (not shown). pulled out. It is preferable that the guide path 160 is formed in a concave shape, and that the flow path fitted therein can be visually recognized from above in a state in which the flow path guide portion 16 is pulled out. The concave shape is not particularly limited, but any shape that can accommodate the flow path, such as a U-shape or a V-shape, may be used.

Here, the effect of the flow-path guide|induction part 16 of 1st embodiment is demonstrated. The first embodiment contributes to a reduction in the outer dimensions of the entire device by movably pulling out the flow path guiding portion 16 . By providing the flow channel outlet 162 on the upper side of the device instead of on the back side of the device, and routing the flow channel toward the flow channel outlet 162 by the flow channel guide portion 16, the flow channel extends in the front-rear direction inside the device. It is no longer necessary to provide a crossing space, and electrical components included in the radiopharmaceutical administration device 1 (for example, uninterruptible power supply (UPS) 70a, control unit 70b, etc.) are placed in the newly created space. Because you can. As a result, the vertical dimension of the entire radiopharmaceutical administration apparatus can be reduced.
In addition, the first embodiment contributes to improved operability for the operator by movably pulling out the flow path guiding portion 16 . That is, when setting the flow path forming member in the radiopharmaceutical administration device 1 for administering the radiopharmaceutical 27 to the living body, the operator pulls out the flow path guiding portion 16 to the side of the device without moving from the front of the device. Therefore, the flow path can be accommodated in the concave guide path 160 and routed. Further, by forming the guiding path 160 in a concave shape, the accommodated flow path can be visually recognized, and the setting of the flow path constituting members can be facilitated. Also, in the first embodiment, an example in which the guideway 160 accommodates only the radioactive channel 31b has been described, but the saline channel 31a and the radioactive channel 31b may be accommodated together.

(shielding member)
Next, the shielding member 21 will be described with reference to FIGS. 3 to 5. FIG. In the first embodiment, the radiopharmaceutical administration device 1 has a shielding member 21 as a configuration for reducing leakage of radiation to the outside. The shielding member 21 covers at least a part of the container placement portion 12 (shielding region S1) and the flow path component placement portion 14 (shielding region S2), and has shielding walls 21a to 21m as its outer walls. One side surface of the shielding member 21 on the front side of the device is shielding doors 10a and 10b that individually open or close the container arrangement portion 12 and the flow path component arrangement portion . Here, the materials of the shielding walls 21a to 21k and the shielding doors 10a and 10b are not particularly limited as long as they have a radiation stopping power capable of shielding radiation (eg, gamma rays, X-rays, etc.), but aluminum is preferable. , lead, and tungsten. Aluminum and tungsten are preferable from the viewpoint of weight per unit volume, and aluminum and lead are preferable from the viewpoint of ease of processing. Each shielding wall or shielding door may be made of a single material, or may be made of two or more materials having different radiation stopping powers.

A shielding region S1 formed by covering at least a portion of the container placement portion 12 with the shielding member 21 will be described with reference to FIGS. 3, 4, and 5. FIG. In addition to shielding door 10b not shown in FIG. a shielding wall 21b covering the shielding area S1, a shielding wall 21c close to the rear side of the needle unit placement portion 124 and the container holder 122 and covering the shielding area S1, and a shielding wall 21d covering the left side surface of the needle unit placement portion 124. is formed by Below the shielding wall 21d, there is an opening (not shown) for mounting the detachable cassette 13 mounted with the passage forming member. The shielding wall 21b also has an opening 24 below it. This is because the leakage of radiation in the lateral direction of the shielding container 5 is sufficiently reduced by the shielding container 5 itself. For the same reason, there is no shielding wall below the container placement portion 12 (-z direction in FIG. 3). By appropriately providing an opening or the like in consideration of the radiation stopping power of each wall surface, the total volume of the shielding area S1 can be reduced, and the outer dimensions of the radiopharmaceutical administration apparatus 1 as a whole can be reduced.

Next, the shielding member 21 that covers the flow path forming member placement portion 14 will be described. In addition to the shielding door 10a on the front side not shown in FIG. The shielding wall 21e that covers the shielding region S2 in close proximity to the side surface, the shielding wall 21f that covers the shielding region S2 in proximity to the left side surface of the syringe drive unit 142, and the lower left side surface of the flow path component holding unit 144, the air A shielding wall 21h that covers the shielding region S2 close to the left side of the vented filter 32, a hole that connects the shielding wall 21f and the shielding wall 21h, and allows the saline solution channel 31a and the radioactive channel 31b to pass through (Fig. 1 , a shielding wall 21g that is close to the right side surface of the flow path switching member holding portion 146 and covers the shielding area S2, and a bottom surface of the flow path forming member placement portion 14 A shielding wall 21j covering the shielding area S2 and a shielding wall 21k covering the shielding area S2 close to the back side of the flow path component placement portion 14 are provided. In addition, the shielding wall 21c covering the back side of the container placement section 12 and the shielding wall 21k covering the back side of the flow path component placement section 14 are provided in parallel with each other. are provided on different planes separated in the front-rear direction by a distance corresponding to the length of the connecting member 139 of the detachable cassette 13 in the depth direction.

The shielding door 10a that opens or closes the flow path component arrangement portion 14 may be single, but is preferably composed of a plurality of outer doors 100 and inner doors 110 as shown in FIG. be. In the first embodiment, the shielding door 10a is a plurality of shielding doors consisting of an outer door 100 and an inner door 110, which are provided so as to overlap each other. The material of each shielding door is a shielding member having a radiation stopping power. In the first embodiment, the inner door 110 is made of a single material having a high radiation stopping power, and the outer door 100 includes an A layer 100a having a high radiation stopping power and a B layer having a lower radiation stopping power than the A layer. It is made of two kinds of materials of 100b. The inner door 110 and the A layer 100a of the outer door 100 are preferably made of the same material.

Next, the positional relationship between the outer shielding door 100 and the inner shielding door 110 that cover the flow passage component arrangement portion 14 will be described. As shown in FIG. 4, the inner shielding door 110 covers the flow channel component holding portion 144 (FIGS. 3 and 7) and the flow channel switching member holding portion 146 (FIG. 3) of the flow channel component placement portion 14, An outer door 100 is provided so as to overlap the outer side (rightward direction in FIG. 4), and the outer door 100 covers the syringe driving section 142 and the inner door 110 . More specifically, the A layer 100 a of the outer door 100 covers the syringe driver 142 and the B layer 100 b covers the syringe driver 142 and the inner door 110 . Further, the upper ends of the outer door 100 (a part of the A layer and the B layer) and the inner door 110 are provided with steps so as to engage with each other.

The radiation stopping power of the inner door 110 is formed to be higher than the radiation stopping power of the outer door 100 (A layer 100a and B layer 100b). When these shielding doors are arranged in descending order of radiation stopping power, the order is the inner door 110, the A layer 100a of the outer door, and the B layer 100b. This is because the radioactive drug 27 passes from the vial bottle 7 through the channel 31d and over the radioactive channel 31b of the detachable cassette 13 fitted to the channel component holder 144. FIG. In the syringe drive unit 142 in which the radiopharmaceutical 27 does not pass in the vicinity, and the flow path forming member holding unit 144 and the flow path switching member holding unit 146 in which the radiopharmaceutical 27 passes in the vicinity, the flow path forming member holding unit 144 and the flow path switching The amount of radioactivity in member holding portion 146 is higher. That is, an area with a high radiation dose is covered with an inner door 110 formed to have a high radiation stopping power, and an area with a low radiation dose is covered with an outer door 100 formed so as to have a radiation stopping power lower than that of the inner door 110. By covering with , the total volume of the shielding area S2 can be reduced, and the overall outer dimensions of the radiopharmaceutical administration apparatus 1 can be reduced.

(Loose insertion space (notch area))
Next, the cutout region 210 and the loose insertion space 50 created by the cutout region 210 will be described. The notch area 210 is composed of shielding walls 21f and 21g. The cutout region 210 is not formed by “notching” a part of the shielding member 21, but if the shielding member 21 is conceptually rectangular parallelepiped, the shielding member 21 is formed by a part of the rectangular parallelepiped. The portion corresponding to the missing portion is called a cutout region because it has a shape that looks like a missing portion. The notch region 210 is formed by designing the shielding wall 21g to be lower than the shielding wall 21e, and by using the shielding wall 21e as the high surface portion 211a shown in FIG. 1 and the shielding wall 21f as the low surface portion 211b. Since the cutout region 210 is not a member having a substance but a space, the loose insertion space 50 is generated overlapping the cutout region 210 . The loose insertion space 50 is a space into which the radioactive flow path 31b having a length considering that it is pulled out together with the flow path guiding portion 16 is gently inserted (loosely inserted) in a bent state.

In addition, the above-described configuration is based on the flow path constituent members (the first syringe 36a, the second syringe 36b, the air vented filter 32, the saline flow path 31a, the radioactive flow path 31b and the This is because the path switching members 33a, 33b, 33c) are different in size and installation range. That is, it is necessary to secure a height at which the plunger fitting portions 143a and 143b move up and down in the area where the syringe driving portion 142 is located in the flow path forming member placement portion 14 . On the other hand, the area where the air vented filter 32 is located does not need to have a height for vertical movement. The inventors of the present invention paid attention to such a point, and instead of adjusting the shielding member 21 to fit the size of each flow path constituting member, the shielding member 21 was removed from the unnecessary space. excluding space. By making the removed space outside the shielding member 21, the exclusive volume of the shielding region S2 can be reduced. In the first embodiment, the resulting loose insertion space 50 is used to route the radioactive channel 31b, and the space that has been used for routing the channel has another electrical configuration (uninterruptible power supply (UPS) 70a, etc.), the outer dimensions of the radiopharmaceutical administration device 1 can be reduced.

(motion)
Next, the operation during administration of the radiopharmaceutical administration apparatus 1 having the configuration described above will be described. In this description of operation, the shielding container 5 is placed on the container holder 122, and the flow path constituting members (the first syringe 36a, the second syringe 36b, the air vented filter 32, the saline flow path 31a, the radioactive flow path 31b). and channel switching members 33a, 33b, and 33c) is attached to the channel-constituting member arrangement portion 14, and a certain amount of physiological saline solution sucked from the saline bag 3 is placed in the second syringe 36b. It shall be in a stored state. Further, in the first embodiment, when the operator touches a display indicating "start administration" or the like displayed on the display 65, the control unit 70b detects the contact pressure on the display 65, and the preset administration program ( Hereinafter, a case where the administration is started by activating a program will be described, but the means for notifying the control unit 70b of the start of administration is not limited to this.

The control unit 70b starts the program, first operates the needle driving mechanism 129, and lowers the first needle holding portion 127a with the medicine extracting needle 125 attached and the second needle holding portion 127b with the aeration needle 126 attached. By driving in the direction, the needle tip of the drug extracting needle 125 penetrates the stopper of the vial bottle 7 and descends to near the bottom of the tilted vial bottle 7 . At this time, the channel switching member 33b communicates the first syringe 36a with the channel 31d, the first syringe 36a and the vial 7 are communicated through the channel 31d, and the vial is The inside of 7 is kept at normal pressure.

Next, according to the program, the controller 70b rotates the motor 300 by a preset number of revolutions to raise the plunger 37a of the first syringe 36a. As a result, the radiopharmaceutical 27 is sucked into the first syringe 36a from the vial bottle 7 through the drug extracting needle 125, the flow path 31d, the flow path switching member 33a, and the flow path switching member 33b in an amount corresponding to the number of rotations of the motor.

Next, the controller 70b operates the needle drive mechanism 129 according to the program to raise the drug extracting needle 125 to a position in the vial bottle 7 sufficiently away from the liquid surface of the radioactive drug 27 . After that, the motor 300 is further rotated to raise the plunger 37a of the first syringe 36a, and a predetermined amount of air is supplied to the vent needle 126, the vial bottle 7, the drug extracting needle 125, the channel 31d, the channel switching member 33a, The liquid is sucked into the first syringe 36a through the channel switching member 33b. As a result, the amount of radiopharmaceutical remaining in drug extraction needle 125, channel 31d, channel switching member 33a, and channel switching member 33b is reduced, and a desired amount of radiopharmaceutical 27 can be aspirated.

Next, according to the program, the control unit 70b rotates the motor 310 to rotate the flow channel switching member 33b, thereby communicating the first syringe 36a with the radioactive flow channel 31b, the total volume flow channel 31c, and the air vented filter 32. Subsequently, the control unit 70b rotates the motor 300 to lower the plunger portion 37a of the first syringe 36a, thereby delivering the entire amount of the radioactive drug 27 stored in the first syringe 36a to the entire flow path 31c. As a result, the radiopharmaceutical 27 advances through the total amount flow path 31 c and passes through the air vented filter 32 . The air sucked into the first syringe 36 a at this time is removed by the air vented filter 32 . The radiopharmaceutical 27 that has passed through the air vented filter 32 is administered to the living body through the radiological channel 31b.

Next, the control unit 70b rotates the motor 310 according to the program to connect the flow path switching members 33a and 33b. Also, the motor 310 is rotated to communicate the flow path switching member 33a and the second syringe 36b. As a result, the first syringe 36a and the second syringe 36b communicate with each other through the channel switching member 33a and the channel switching member 33b. Next, the motor 300 is rotated by a preset number of revolutions to raise the plunger portion 37a of the first syringe 36a to draw the physiological saline stored in the second syringe 36b into the first syringe 36a. At this time, the motor 300 that drives the plunger portion 37b of the second syringe 36b is reversely rotated by the same amount as the movement amount of the motor that drives the plunger portion 37a of the first syringe 36a, thereby lowering the plunger portion 37b of the second syringe 36b. Let

Next, according to the program, the control unit 70b rotates the motor 310 to rotate the flow path switching member 33b, thereby connecting the full flow path 31c and the first syringe 36a. Then, the motor 300 is rotated by a preset number of revolutions to lower the plunger 37a of the first syringe 36a, thereby delivering the physiological saline stored in the first syringe 36a to the total amount flow path 31c. The delivered physiological saline solution advances through the total flow channel 31c, the air vented filter 32, and the radioactive flow channel 31b and is administered to the living body. As a result, the inside of the first syringe 36a, the total amount flow path 31c, the air vented filter 32, and the radioactive flow path 31b can be washed with the physiological saline solution, and as much of the radiopharmaceutical remaining in the flow path as possible can be administered to the living body. becomes possible. The above operation completes administration of the radiopharmaceutical 27 to the living body.

In addition, the operation of the first embodiment is not limited to the above. to communicate with a waste channel (not shown) and the first syringe 36a, and the remainder may be delivered to the waste channel. In this case, the radiopharmaceutical 27 that has not been administered to the living body advances through the waste channel and is stored in the waste liquid bottle 180 .

Further, in the first embodiment, an example in which the flow path forming member is indirectly attached to the radiopharmaceutical administration device 1 via the detachable cassette 13 was shown, but the present invention is not limited to such a configuration. Alternatively, the flow path forming member may be attached directly to the radiopharmaceutical administration device. In that case, each holding portion provided in the detachable cassette 13 may be provided in the flow path forming member arrangement portion 14 of the apparatus main body.

[Variation]
Also, in the first embodiment, an example in which the container holder 122 is provided in the device housing 20 has been described, but the present invention is not limited to such a configuration.
FIG. 9 is a diagram showing a modification of the container holder of the first embodiment. In the first embodiment, as shown in FIG. 9, the container holder may be a container holder 222 provided on the inner door 110 that constitutes the shield door 10b of the shield doors 10. As shown in FIG. By configuring in this way, the first embodiment can reduce the transportation distance of the shielding container 5, which is generally a heavy object, and can be expected to improve the operability of the operator.

[Second embodiment]
Next, a second embodiment of the invention will be described. The radiopharmaceutical administration device 1 of the second embodiment is the same as that of the first embodiment except for the configuration of the needle unit. Therefore, in the second embodiment, illustration and description of the configuration other than the detachable cassette and the needle unit are partially omitted.
The flow path forming member of the second embodiment is indirectly attached to the radiopharmaceutical administration device 1 via the detachable cassette 43 as in the first embodiment. FIG. 10 is a bottom view of the detachable cassette 43, FIG. 11 is a front view of the detachable cassette 43 with flow path forming members attached thereto, and FIG. 12 is a rear view thereof. Here, as shown in FIG. 10, in the second embodiment, the main board 430 and the sub-board 431 of the detachable cassette 43 are connected by connecting members 439 in an L-shape. That is, the first needle holding portion (not shown) and the second needle holding portion (not shown) provided on the sub-board 431 of the detachable cassette 43 are arranged in the normal direction to the main board 430 (the front-to-rear direction when attached to the device). are placed in As a result, the widthwise dimension of the detachable cassette 43 can be shortened, the widthwise dimension of the shielding area S2 of the device housing in which the detachable cassette 43 is mounted can be shortened, and the widthwise outer dimension of the radiopharmaceutical administration device can be shortened. can be made smaller.
Further, in this case, it is preferable that the inclined surface 123 of the container holder 122 of the container placement portion 12 is provided in the same direction as the needle holding portions are arranged.

13(a) and 13(b) are diagrams for explaining the needle unit 228 of the second embodiment. The needle unit 228 holds the first needle holding portion 127a, which is the extraction needle holding portion, and the second needle holding portion 127b, which is the aeration needle holding portion, so as to be arranged in the front-rear direction crossing the width direction of the apparatus housing. It has guide holes 434a and 434b, which are needle guides that move up and down. Here, the front-rear direction is a direction intersecting with the x, y plane shown in FIGS. 1 to 5, preferably the y direction, or approximately the y direction. The first needle holding portion 127a is configured to hold the drug extraction needle 125, and the second needle holding portion 127b is configured to hold the aeration needle 126. As shown in FIG. FIG. 13(a) shows the state before the medicine extraction needle 125 and the ventilation needle 126 are lowered, and FIG. 13(b) shows the medicine extraction needle 125 and the ventilation needle 126 are lowered.

As shown in FIGS. 13(a) and 13(b), the needle unit 228 has the first needle holding portion 127a and the second needle holding portion 127b arranged in a direction crossing the width direction of the device housing 20. It has a needle guide portion that moves up and down while holding it like this. The needle guide portion of the second embodiment is a first guide groove (guide hole) 434a and a second guide groove (guide hole) 434b extending in the vertical direction. In the second embodiment, the guide hole 434b is formed so as to bend near the center in a direction approaching the guide hole 434a. However, in the second embodiment, on the contrary, the guide hole 434b may be formed so as to bend toward the guide hole 434a. With this configuration, in the second embodiment, the needle unit 228 can be attached so as to extend in the depth direction of the radiopharmaceutical administration device 1, so that the needle unit 228 occupies the width direction of the radiopharmaceutical administration device 1. Installation space can be reduced.

In addition, the drug extracting needle 125 and the ventilation needle 126 are in a state of being covered with a cap until immediately before being attached to the radiopharmaceutical administration apparatus 1 . In a known radiopharmaceutical administration device, the capped drug extraction needle 125 and ventilation needle 126 cannot be attached in the state shown in FIG. It had to be attached to the drug administration device 1 . For this reason, in the known radiopharmaceutical administration device 1, care must be taken not to prick the operator's finger with the needle when the drug extraction needle 125 and the ventilation needle 126 are attached.
On the other hand, in the needle unit 228 of the second embodiment, as shown in FIG. Both can be attached to the radiopharmaceutical administration device 1 with the cap on 126 . Such a second embodiment can reduce the operator's risk of needlestick when attaching the drug extraction needle 125 and the ventilation needle 126 to the detachable cassette 43 or attaching the detachable cassette 43 to the device housing 20 .

The above embodiment includes the following technical ideas.
(1) A radiopharmaceutical administration device for administering a radiopharmaceutical to a living body, comprising: a container holding portion holding a shielded container in which a drug container of the radiopharmaceutical is accommodated; A configuration mounting portion to which a plurality of flow channel constituting members constituting a portion of a flow channel connected to a drug container are mounted; and a device housing that covers at least part of the shielding member, wherein the shielding member has a lower surface part in which a part of the upper surface in the installation direction is lower than the other part of the upper surface. A radiopharmaceutical administration device having a loose insertion space above the low surface portion into which the flow path drawn out from the shielding member is loosely inserted.
(2) The radiopharmaceutical administration device according to (1), wherein the shielding member is provided with a plurality of shielding areas for individually shielding the container holding portion and the component mounting portion.
(3) of (1) or (2), further comprising a flow path guiding portion that holds the flow path between a first opening formed in the shielding member and a second opening formed in the device housing; Radiopharmaceutical administration device.
(4) The radiopharmaceutical administration device according to (3), wherein the flow channel guide section allows the flow channel to move in the width direction of the device housing.
(5) The radiopharmaceutical administration device according to any one of (1) to (4), wherein part of the flow path is routed upward and in the width direction of the device housing within the loose insertion space.
(6) The shielding member has a plurality of shielding walls that form a shielding space, and a shielding door that opens or closes the shielding space. and an inner door that faces an inner surface that is the back surface of the outer door with respect to the outer surface.
(7) The configuration mounting section includes one or more syringe driving sections for driving a plunger section of a syringe for extracting the radiopharmaceutical from the shielded container through the flow path; a flow path switching member holding section for holding a flow path switching member for switching flow paths, wherein the inner door covers the flow path switching member holding section; and the outer door includes the syringe driving section and the inner door. covering the radiopharmaceutical administration device of (6).
(8) The radiopharmaceutical administration device according to (6) or (7), wherein the radiation stopping power of the inner door is higher than the radiation stopping power of the outer door.
(9) The radiopharmaceutical administration device according to any one of (6) to (8), wherein the container holding section is provided on the inner side door of the shielding door.
(10) A needle unit that detachably holds an extraction needle holding section that holds an extraction needle for extracting the radioactive drug from the drug container, and an aeration needle holding section that holds an aeration needle that is punctured into the drug container. The needle unit further includes a needle guide portion that moves up and down while holding the extraction needle holding portion and the aeration needle holding portion so as to be arranged in a front-rear direction that intersects the width direction of the device housing, The radiopharmaceutical administration device according to any one of (1) to (9).
(11) The needle guide portion is a guide groove extending in the vertical direction, and includes a first guide groove in which one of the extraction needle holding portion and the aeration needle holding portion moves and a second guide groove in which the other moves. and one of the first guide groove and the second guide groove is bent in a direction approaching the other.

Reference Signs List 1 Radiopharmaceutical administration device 3 Saline bag 5 Shielding container 6 Operation unit 7 Vial bottles 10, 10a, 10b Shielding door 10c Waste liquid bottle storage door 10d... Flow path housing doors 10cc, 10dd, 11... Grasping part 12... Container placement parts 13, 43... Removable cassette 14... Flow path component placement part 16... Flow path guidance Portion 17 Handle portion 18 Waste liquid bottle arrangement portion 19 Mounting hole 20 Apparatus housing 21 Shielding members 21a to 21q Shielding wall 24 Opening 27 Radiopharmaceutical 31a Saline solution channel 31b Radioactive channel 31c Total flow channels 33a, 33b, 33c Channel switching member 31d Channel 32 Air vented filter 34... Connector 35... Suspension base 36a... First syringe 36b... Second syringes 37a, 37b... Plunger part 40... Printer 50... Loose insertion space 62... Emergency stop switch 63 external communication connector 64 power switch 65 display 70a uninterruptible power supply 70b control unit 70c transformer 100 outer door 100a A layer 100b...B layer 110...inner door 122...container holder 123...slanted surface 124...needle unit arrangement portion 125...medicine extraction needle 126...venting needle 127... Needle holding portions 127a, 427a First needle holding portions 127b, 427b Second needle holding portion 128 Needle unit 129 Needle driving mechanisms 130, 430 Main substrates 131, 431 Sub-board 132 Tube holding portion 133 Needle guide portions 134a, 134b Guide hole 135 Switching member holding portion 136 Syringe holding portion 136a First syringe holding portion 136b...Second syringe holding part 138...Filter holding parts 139, 439...Connecting member 142...Syringe drive parts 143a, 143b...Plunger fitting part 144...Flow passage forming member holding Portion 146 Flow path switching member holding parts 147a, 147b Opening 160 Guidance path 161 Flow path inlet 162 Flow path outlet 180 Waste liquid bottle 201 Second opening 210 Notch region 211 Top surface 211a High surface portion 211b Low surface portion 211c First opening 211d Opening 222 Container holder 228 Needle unit 300, 310... Motor 434a, 434b... Guide holes S1, S2... Shielding area

Claims (11)

A radiopharmaceutical administration device for administering a radiopharmaceutical to a living body,
A container holding unit that holds a shielding container in which the drug container of the radioactive drug is accommodated;
a configuration mounting section to which a plurality of flow path constituting members that form part of a flow path connected to the drug container housed in the container holding section are mounted;
a shielding member that covers at least a portion of the container holding portion or the structural attachment portion and shields radiation emitted from the radiopharmaceutical;
a device housing covering at least a portion of the shielding member;
The shielding member has a lower surface part in which a part of the upper surface in the installation direction is lower than the other part of the upper surface, and the flow path drawn out from the shielding member is loosely inserted above the lower surface part. A radiopharmaceutical administration device having a space. 2. The radiopharmaceutical administration device according to claim 1, wherein the shielding member is provided with a plurality of shielding areas for individually shielding the container holding portion and the component mounting portion. 3. The radiopharmaceutical administration according to claim 1 or 2, further comprising a channel guiding portion that holds the channel between a first opening formed in the shielding member and a second opening formed in the device housing. Device. 4. The radiopharmaceutical administration device according to claim 3, wherein said flow path guide section allows said flow path to move in the width direction of said device housing. 5. The radiopharmaceutical administration device according to any one of claims 1 to 4, wherein part of said flow path is routed upward and in the width direction of said device housing in said loose insertion space. The shielding member has a plurality of shielding walls that form a shielding space and a shielding door that opens or closes the shielding space,
6. Any one of claims 1 to 5, wherein the shielding door includes an outer door having an outer surface exposed to the outside of the radiopharmaceutical administration apparatus, and an inner door facing the inner surface that is the back surface of the outer door with respect to the outer surface. 1. The radiopharmaceutical administration device according to claim 1. The mounting portion includes one or more syringe drivers for driving a plunger portion of a syringe to extract the radiopharmaceutical from the shielded container through the channel; A channel switching member holding portion for holding a channel switching member to be switched is attached, the inner door covers the channel switching member holding portion, and the outer door covers the syringe driving portion and the inner door. 7. The radiopharmaceutical administration device according to claim 6, wherein 8. The radiopharmaceutical administration device according to claim 6, wherein the radiation stopping power of the inner door is higher than the radiation stopping power of the outer door. The radiopharmaceutical administration device according to any one of claims 6 to 8, wherein the container holding section is provided on the inner side door of the shielding door. a needle unit that detachably holds an extraction needle holding part that holds an extraction needle for extracting the radioactive drug from the drug container and a ventilation needle holding part that holds a ventilation needle that is pierced by the drug container;
2. The needle unit has a needle guide portion for moving up and down while holding the extraction needle holding portion and the aeration needle holding portion so as to be arranged in a front-rear direction crossing the width direction of the device housing. 10. The radiopharmaceutical administration device according to any one of 9. The needle guide portion is a guide groove extending in the vertical direction, and includes a first guide groove in which one of the extraction needle holding portion and the aeration needle holding portion moves, and a second guide groove in which the other moves. 11. The radiopharmaceutical administration device according to claim 10, wherein one of said first guide groove and said second guide groove is bent in a direction approaching the other.

Images